Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$79,510.00-1.01%ETH$2,300.10-1.19%GOLD$4,007.30-0.77%OIL$102.44+0.67%
Smart Investors Daily
SID Premium
AN

NASDAQ · ANL

Adlai Nortye Ltd.

Healthcare · Biotechnology

$10.58

Up+$0.00 (+0.00%)

Updated Oct 27, 2026, 10:12 AM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
245.52M
P/E ratio
-1.61
Dividend yield
0.00%
52-week range
$0.88 – $17.25
Volume
132.94K
Avg. volume
920.81K

Price performance · ANL

ANL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

ANL closed at $10.58 after 21 trading sessions, down 31.30% for the selected period.

Last close
$10.58
Period change
-31.30%
Period low
$10.38
Period high
$16.00
Daily close
View OHLC price history
ANL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$10.71$10.88$10.40$10.58132.94K
Oct 23, 2026$10.55$10.65$10.30$10.5879.54K
Oct 22, 2026$11.01$11.22$10.58$10.58169.97K
Oct 21, 2026$10.80$11.68$10.80$11.26532.6K
Oct 20, 2026$10.37$11.32$10.37$10.64242.56K
Oct 19, 2026$10.97$11.38$10.34$10.38356.48K
Oct 16, 2026$11.89$12.04$10.93$11.03336.59K
Oct 15, 2026$11.23$12.4574$11.23$12.09864.17K
Oct 14, 2026$11.88$12.11$10.80$10.88378.01K
Oct 13, 2026$14.20$14.20$11.40$11.755957.74K
Oct 12, 2026$15.65$16.22$13.91$14.22415.71K
Oct 9, 2026$15.33$16.735$14.87$15.62300.44K
Oct 8, 2026$13.87$16.05$13.78$15.51985.26K
Oct 7, 2026$14.41$15.04$14.03$14.0595.06K
Oct 6, 2026$15.03$15.68$14.23$14.4699.77K
Oct 5, 2026$14.80$15.82$14.34$15.04460.58K
Oct 2, 2026$15.76$15.80$14.825$15.0977K
Oct 1, 2026$16.00$16.20$15.5358$15.76124.79K
Sep 30, 2026$15.87$16.31$15.50$16.0093.95K
Sep 29, 2026$15.26$15.82$15.11$15.6563.03K
Sep 28, 2026$15.70$15.855$15.095$15.4063.51K

Latest ANL news

The latest Smart Investors Daily articles mentioning ANL.

Stock researchCompany · Overview

ANL research

Overview

Company profile and research snapshot.

Company profile

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
ANL recent ratings
DateFirmRatingTarget
Sep 10, 2026JefferiesBuy—
Sep 8, 2026HC Wainwright & Co.Buy—
Jun 22, 2026Cantor FitzgeraldOverweight—
May 28, 2026OppenheimerOutperform—
May 14, 2026Jones TradingBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 15, 2026

Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial Cetuximab will be supplied by Lilly for the U.S. trial sites Cetuximab will be supplied by Merck KGaA, Darmstadt, Germany for the Australia and China trial sites SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By